Abstract: The present invention relates to methods for promoting somatic embryogenesis from a tissue or organ of a plant, by overexpressing a Wuschel gene in said tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants.
Abstract: The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.
Type:
Grant
Filed:
July 6, 2009
Date of Patent:
January 3, 2012
Assignee:
The Rockefeller University
Inventors:
Markus Stoffel, Matthew N. Poy, Thomas H. Tuschl
Abstract: The invention relates to isolated nucleic acid molecules comprising the sequence of a human cytomegalovirus microRNA. In another embodiment, the invention relates to single stranded DNA virus microRNA molecules comprising the sequence of a human cytomegalovirus microRNA. The invention also relates to the anti-DNA virus microRNA molecules.
Abstract: Sequences are provided that are capable of directing circular adeno-associated virus replication, useful in vectors for providing therapeutic agents to a subject in need thereof. The vectors of the invention are particularly useful in the treatment of acute medical conditions requiring rapid gene expression. Further provided are methods for producing packaged defective viral vectors.
Abstract: The preferred embodiments of the present invention include a holography attachment device that is attachable to a digital imaging device to form a holographic microscope. The holography attachment device includes a chamber having at least one attachment mechanism to facilitate attachment of the chamber to a digital imaging device. The holography attachment device also includes a light source and a sample holder section, which is located between a proximate end and the distal end of the chamber. The light source is configured to radiate light within the chamber. The light passes through the sample holder section and impinges on an imaging sensor of a digital imaging device when the chamber is attached to the digital imaging device. The digital imaging device is capable of recording hologram information related to a sample held by the sample holder in the sample holder section.
Abstract: The present invention is directed to methods of treating Type I diabetes by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods treating Type 2 diabetes comprising the step of administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is further directed to methods treating insulin resistance comprising the step of administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is directed to methods of treating hepatic steatosis by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods lowering blood glucose and serum insulin in non-diabetic subjects comprising the step of administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2.
Abstract: This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for influenza viral infection.
Type:
Grant
Filed:
January 23, 2008
Date of Patent:
October 4, 2011
Assignees:
Academia Sinica, The Rockefeller University
Inventors:
David D. Ho, Yaoxing Huang, Ming Wei Chen, Rachel TJ Cheng, Chi-Huey Wong, Alice Yu
Abstract: The present invention describes a method of identifying inducible genetic regulatory sequences that can control the transcription of specific gene transcripts. Methods of using inducible genetic regulatory sequences are also discussed. In particular, the genetic regulatory sequences of the present invention can modulate the transcription of a nucleic acid transcript in vivo.
Type:
Grant
Filed:
October 3, 2006
Date of Patent:
September 20, 2011
Assignees:
The Rockefeller University, Thomas Jefferson University, Neurologix Research, Inc.
Inventors:
Michael G. Kaplitt, Matthew J. During, Andres M. Lozano
Abstract: The invention relates to the discovery that the Claudin-1 protein functions as a co-receptor for entry of HCV into cells. Methods of inhibiting, preventing or mitigating HCV infections by inhibiting HCV interactions with Claudin-1 are provided. Methods of identifying agents or compounds that interfere with HCV interactions with Claudin-1 are also provided. Finally, useful kits, cell culture compositions, agents, and compounds related to the inhibition of HCV interactions with Claudin-1 are also disclosed.
Type:
Grant
Filed:
May 4, 2007
Date of Patent:
September 20, 2011
Assignee:
The Rockefeller University
Inventors:
Charles Rice, Matthew J. Evans, Thomas Von Hahn
Abstract: The present invention provides a novel family of polypeptides which are ligand-gated channel receptor accessory molecules or ligands, denoted Lynx. This invention provides an isolated polypeptide comprising an amino acid sequence of a Lynx polypeptide in which the amino acid sequence is set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:15, including fragments, mutants, variants, analogs, homologs, or derivatives of the amino acid sequences set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:15. This invention further provides an isolated immunogenic polypeptide; an isolated nucleic acid; pharmaceutical compositions and diagnostic and therapeutic methods of use of the isolated polypeptides and nucleic acids of the present invention; assays for compounds which mimic, alter or inactivate the polypeptides of the present invention for use in therapy; and methods of isolating Lynx polypeptides and the nucleic acids encoding such polypeptides.
Type:
Grant
Filed:
December 18, 2002
Date of Patent:
September 6, 2011
Assignee:
The Rockefeller University
Inventors:
Nathaniel Heintz, Julie M. Miwa, Ines Ibanez-Tallon
Abstract: Modulators of weight, including, for example, two isoforms of murine and human ob polypeptides, are provided, as well as diagnostic and therapeutic uses and methods comprising such. Also provided are nucleotide sequences, degenerate variations thereof, and proteins expressed by such.
Type:
Grant
Filed:
April 21, 2009
Date of Patent:
August 9, 2011
Assignee:
The Rockefeller University
Inventors:
Jeffrey M. Friedman, Yiying Zhang, Ricardo Proenca
Abstract: This invention relates to methods and compositions useful for delivering antigens to dendritic cells which are then useful for inducing antigen-specific cytotoxic T lymphocytes and T helper cells. This invention also provides assays for evaluating the activity of cytotoxic T lymphocytes. According to the invention, antigens are targeted to dendritic cells by apoptotic cells which may also be modified to express non-native antigens for presentation to the dendritic cells. The dendritic cells which are primed by the apoptotic cells are capable of processing and presenting the processed antigen and inducing cytotoxic T lymphocyte activity or may also be used in vaccine therapies.
Type:
Grant
Filed:
June 9, 2006
Date of Patent:
August 2, 2011
Assignee:
The Rockefeller University
Inventors:
Matthew L. Albert, Nina Bhardwaj, Ralph M. Steinman, Kayo Inaba, Robert Darnell
Abstract: This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for influenza viral infection.
Type:
Grant
Filed:
April 2, 2009
Date of Patent:
July 19, 2011
Assignees:
Academia Sinica, The Rockefeller University
Inventors:
Chi-Huey Wong, David D. Ho, Yaoxing Huang, Ting-Jen R. Cheng, Ming Wei Chen, Alice Yu
Abstract: The present invention relates to methods for promoting somatic embryogenesis from a tissue or organ of a plant, by overexpressing a Wuschel gene in said tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants.
Abstract: The present invention is method of determining whether or not associations between a given protein and other proteins in a cell are specific.
Type:
Grant
Filed:
August 21, 2006
Date of Patent:
June 28, 2011
Assignee:
The Rockefeller University
Inventors:
Brian T. Chait, Alan J. Tackett, Jeffrey A. DeGrasse, Marlene Oeffinger, Michael P. Rout, Matthew D. Sekedat
Abstract: The invention provides a water soluble complex comprising an inner core of a metal or semi-conductor nanoparticle. The nanoparticle is coated with a hydrophobic ligand, which is encapsulated in a micelle. In an aqueous medium, the micelle comprises a hydrophilic shell and a hydrophobic core, the hydrophilic shell comprising a plurality of hydrophilic moieties, the hydrophobic core comprising a plurality of hydrophobic moieties, each hydrophobic moiety comprising at least one chain, each chain comprising a minimum of 8 atoms; wherein the total number of atoms in all chains for each moiety comprises at least 24 atoms. The micelle has a minimum average diameter of approximately 5 nm and a maximum average diameter of approximately 45 nm.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
May 31, 2011
Assignee:
The Rockefeller University
Inventors:
Benoit Dubertret, Vincent Noireaux, Albert Libchaber
Abstract: The invention provides a water soluble complex comprising an inner core of a metal or semi-conductor nanoparticle. The nanoparticle is coated with a hydrophobic ligand, which is encapsulated in a micelle. In an aqueous medium, the micelle comprises a hydrophilic shell and a hydrophobic core, the hydrophilic shell comprising a plurality of hydrophilic moieties, the hydrophobic core comprising a plurality of hydrophobic moieties, each hydrophobic moiety comprising at least one chain, each chain comprising a minimum of 8 atoms; wherein the total number of atoms in all chains for each moiety comprises at least 24 atoms. The micelle has a minimum average diameter of approximately 5 nm and a maximum average diameter of approximately 45 nm.
Type:
Grant
Filed:
August 15, 2002
Date of Patent:
May 10, 2011
Assignee:
The Rockefeller University
Inventors:
Benoit Dubertret, Vincent Noireaux, Albert Libchaber
Abstract: This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.
Type:
Grant
Filed:
April 13, 2007
Date of Patent:
April 12, 2011
Assignees:
The Rockefeller University, The Scripps Research Institute
Inventors:
Moriya Tsuji, David D. Ho, Chi-Huey Wong, Douglass Wu, Masakazu Fujio, Xiangming Li
Abstract: A method for producing proliferating cultures of dendritic cell precursors is provided. Also provided is a method for producing mature dendritic cells in culture from the proliferating dendritic cell precursors. The cultures of mature dendritic cells provide an effective means of producing novel T cell dependent antigens comprised of dendritic cell modified antigens or dendritic cells pulsed with antigen, including particulates, which antigen is processed and expressed on the antigen-activated dendritic cell. The novel antigens of the invention may be used as immunogens for vaccines or for the treatment of disease. These antigens may also be used to treat autoimmune diseases such as juvenile diabetes and multiple sclerosis.
Type:
Grant
Filed:
July 17, 2008
Date of Patent:
April 12, 2011
Assignees:
Argos Therapeutics, Inc., The Rockefeller University
Inventors:
Ralph M. Steinman, Kayo Inaba, Gerold Schuler
Abstract: A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN(+) cell to signal a second effector macrophage, causing an increase in expression of the Fc?RIIB receptor and in turn inhibiting a cellular-mediated inflammatory response.